Patents by Inventor Andreas Nandy

Andreas Nandy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9975932
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 9789178
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 17, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Patent number: 9556241
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: January 31, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Helmut Fiebig, Andreas Nandy, Roland Suck, Oliver Cromwell, Arnd Petersen, Wolf-Meinhard Becker
  • Patent number: 9522938
    Abstract: The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: December 20, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Martin Wald, Oliver Cromwell, Andreas Nandy, Helga Kahlert, Bernhard Weber, Helmut Fiebig
  • Patent number: 9309297
    Abstract: The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: April 12, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Patent number: 9120866
    Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: September 1, 2015
    Assignee: MERCK PATENT GMBH
    Inventors: Helmut Fiebig, Andreas Nandy, Roland Suck, Oliver Cromwell, Arnd Petersen, Wolf-Meinhard Becker
  • Publication number: 20150140024
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 21, 2015
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 8999348
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 8945530
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: February 3, 2015
    Assignee: Merck Patent GmbH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Patent number: 8628946
    Abstract: The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterized by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitization) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: January 14, 2014
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Oliver Cromwell, Andreas Nandy, Helga Kahlert, Bernhard Weber, Helmut Fiebig
  • Publication number: 20130224251
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: December 17, 2010
    Publication date: August 29, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 8420097
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: April 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Patent number: 8263090
    Abstract: The present invention relates to the preparation and use of variants of the group 1 allergens of the Poaceae (sweet grasses) which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially maintained reactivity with T-lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventive immunotherapy of grass pollen allergies.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: September 11, 2012
    Assignee: Merck Patent GmbH
    Inventors: Helmut Fiebig, Martin Wald, Andreas Nandy, Helga Kahlert, Bernahrd Weber, Oliver Cromwell
  • Patent number: 8128935
    Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: March 6, 2012
    Assignee: Merck Patent GmbH
    Inventors: Helmut Fiebig, Andreas Nandy, Roland Suck, Oliver Cromwell, Arnd Petersen, Wolf-Meinhard Becker
  • Patent number: 7935347
    Abstract: The invention relates to the preparation of DNA sequences of group 4 major allergens from cereals. The invention also includes fragments, novel combinations of partial sequences and point mutations with hypoallergenic effects. The recombinant DNA molecules and the derived polypeptides, fragments, novel combinations of partial sequences and variants can be used for therapy of pollen-allergy diseases. The proteins produced by recombination can be applied to in-vitro and in-vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: May 3, 2011
    Assignee: Merck Patent GmbH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Patent number: 7846448
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: December 7, 2010
    Assignee: Merck Patent GmbH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Publication number: 20100158955
    Abstract: The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies.
    Type: Application
    Filed: May 6, 2004
    Publication date: June 24, 2010
    Inventors: Martin Wald, Oliver Cromwell, Andreas Nandy, Helga Kahlert, Bernhard Weber, Helmut Fiebig
  • Publication number: 20080267985
    Abstract: The present invention relates to the preparation and use of variants of the group 1 allergens of the Poaceae (sweet grasses) which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially maintained reactivity with T-lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventive immunotherapy of grass pollen allergies.
    Type: Application
    Filed: July 11, 2005
    Publication date: October 30, 2008
    Applicant: MERCK PATENT GMBH
    Inventors: Helmut Fiebig, Martin Wald, Andreas Nandy, Helga Kahlert, Bernahrd Weber, Oliver Cromwell
  • Publication number: 20080108561
    Abstract: The invention relates to the preparation of DNA sequences of group 4 major allergens from cereals. The invention also includes fragments, novel combinations of partial sequences and point mutations with hypoallergenic effects. The recombinant DNA molecules and the derived polypeptides, fragments, novel combinations of partial sequences and variants can be used for therapy of pollen-allergy diseases. The proteins produced by recombination can be applied to in-vitro and in-vivo diagnosis of pollen allergies.
    Type: Application
    Filed: December 1, 2004
    Publication date: May 8, 2008
    Applicant: MERCK PATENT GMBH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Publication number: 20070154496
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Application
    Filed: December 1, 2004
    Publication date: July 5, 2007
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell